Trial Condition(s):

Clinical Pharmacology

Single / multiple dose study in Chinese subjects

Bayer Identifier:

16537

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

Not Available

Study Completed

Trial Purpose

Primary objective was
• to investigate the pharmacokinetics (PK) of finerenone in Chinese healthy male subjects
Secondary objective was
• to investigate the safety and tolerability of finerenone in Chinese healthy male subjects

Inclusion Criteria
- Healthy male Chinese subjects, aged ≥ 18 to ≤ 45 years, with a body mass index (BMI) ≥ 19.0 and  ≤ 24 kg/m^2.
Exclusion Criteria
No Exclusion Criteria Available

Trial Summary

Enrollment Goal
24
Trial Dates
black-arrow
Phase
1
Could I receive a placebo?
Yes
Products
Kerendia (Finerenone, BAY94-8862)
Accepts Healthy Volunteers
Yes

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

The 307th Hospital of Chinese People’s Liberation Army

Beijing, China, 100071

Status
Completed
 

Trial Design